ClearPoint Neuro Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
ClearPoint Neuro s intäkter har minskat med en genomsnittlig årlig takt på -16%, medan Medical Equipment -branschen såg intäkter på växande 18.2% årligen. Intäkterna har varit växande med en genomsnittlig takt på 20.3% per år.
Viktig information
-16.02%
Tillväxttakt i vinsten
-8.67%
Tillväxttakt för EPS
| Medical Equipment Tillväxt i branschen | 8.90% |
| Intäkternas tillväxttakt | 20.35% |
| Avkastning på eget kapital | -320.77% |
| Nettomarginal | -81.76% |
| Senaste uppdateringen av resultatet | 30 Jun 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Uppdatering av berättelse • Sep 03
CLPT: Huntington’s Disease Partner Procedures Will Support Long Term Intracranial Upside
Analysts have trimmed their average price target for ClearPoint Neuro from about $28.33 to $23.50 as they factor in updated targets from Lake Street and Stifel, along with expectations that management's higher ROI investment choices may affect near term growth, while they still see potential support from partner driven opportunities. Analyst Commentary Recent Street research on ClearPoint Neuro reflects a mix of optimism about long term growth potential and caution about the trade off between investment and near term execution.Analysartikel • Aug 06
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported And Analysts Have Been Cutting Their Estimates
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) missed earnings with its latest second-quarter results, disappointing...
Uppdatering av berättelse • Aug 05
CLPT: Huntington’s FDA Path And High ROI Focus Will Support Future Upside
Analysts have trimmed the consolidated price target for ClearPoint Neuro to $22 from $25, reflecting slightly lower modeled revenue growth and profit margins as management focuses on higher ROI projects. These initiatives could weigh on near term results but are still seen as supported by potential partner driven catalysts.Uppdatering av berättelse • Jul 10
CLPT: Huntington’s Disease Partnership Will Drive Future Intracranial Procedure Upside
Analysts have lifted their price target on ClearPoint Neuro to $30 from $20, reflecting updated assumptions around a fair value of about $28.33 per share, a modestly lower discount rate, slightly higher modeled revenue growth, and a higher future P/E multiple tied to expectations for more visible revenue opportunities connected to uniQure's AMT-130 program. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed earnings guidance for 2026 and maintained its expected revenue range of $52 million to $56 million.Uppdatering av berättelse • Jun 26
CLPT: Accelerated Huntington’s Approval Path Will Drive Future Revenue Opportunity
Analysts have lifted their price target on ClearPoint Neuro from $20 to $25, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E in light of ClearPoint's role as a direct beneficiary of the FDA-supported path to accelerated approval for uniQure's AMT-130 in Huntington's disease. What’s in the News for ClearPoint Neuro ClearPoint Neuro reaffirmed its earnings guidance for 2026, maintaining expected revenue in the range of US$52 million to US$56 million.Seeking Alpha • Jun 18
ClearPoint Neuro: AMT-130's FDA Reversal Revives The Bull Case
Summary ClearPoint Neuro remains a speculative Buy, offering leveraged exposure to gene therapy commercialization and neurosurgery navigation growth. Recent FDA feedback on uniQure’s AMT-130 renews optimism for near-term revenue, but regulatory and partner execution risks persist. CLPT’s Q1 organic growth slowed, cash burn accelerated, and full-year 2026 revenue guidance ($52–$56M) disappointed versus expectations. Valuation is premium (8.06x EV/sales), justified by 26.8% projected revenue growth, but profitability hinges on partner drug launches and cash management. Read the full article on Seeking AlphaUppdatering av berättelse • Jun 09
CLPT: Biopharma Partnerships And Intracranial Programs Will Drive Future Upside Potential
Analysts have lifted their price target on ClearPoint Neuro by $2, reflecting updated assumptions around discount rates, profit margins, and long term price-to-earnings (P/E) expectations. What's in the News ClearPoint Neuro reaffirmed revenue guidance for 2026, maintaining an expected range of US$52 million to US$56 million.Uppdatering av berättelse • May 26
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Upside Potential
Narrative Update: ClearPoint Neuro Analyst Price Target Revision Analysts now set a $22 price target for ClearPoint Neuro, down from $25. This reflects slightly lower modeled revenue growth and profit margins, along with a modestly reduced future P/E assumption, even as recent research highlights the company’s broad base of more than 60 biopharma partners and multiple clinical-stage programs with expedited review designations.Uppdatering av berättelse • Apr 20
CLPT: Biopharma Partnerships Will Drive Future Intracranial Program Adoption
ClearPoint Neuro's analyst price target has shifted by $2 as analysts weigh the recent FDA feedback on a partner's program in relation to the company's more than 60 active biopharma relationships and multiple expedited intracranial programs. Analyst Commentary Bullish Takeaways Bullish analysts see the reset price target of $18 per share as supported by what they view as a base business valuation of $12 per share, with additional value tied to pipeline and execution on intracranial programs.Uppdatering av berättelse • Apr 06
CLPT: Biopharma Partnerships And Intracranial Programs Will Support Future Platform Adoption
Analysts have adjusted their price target on ClearPoint Neuro to $25.00, reflecting updated assumptions around the discount rate, margin expectations, and long term P/E benchmarks following recent research commentary. Analyst Commentary Recent research commentary on ClearPoint Neuro highlights a mix of optimism around the core business and caution linked to regulatory outcomes in partner programs, which feeds directly into updated valuation work and risk assumptions.Uppdatering av berättelse • Mar 22
CLPT: Broad Biopharma Partnerships And Intracranial Programs Will Drive Future Upside
Analysts have raised their price target on ClearPoint Neuro to $25 from $24, citing the company’s broad base of more than 60 biopharma partners and multiple clinical-stage intracranial programs as key supports for the updated valuation framework. Analyst Commentary Recent research on ClearPoint Neuro reflects a mix of renewed optimism and lingering caution, with analysts updating their valuation work after regulatory feedback on a key partner trial and reassessing the base business.Ny berättelse • Mar 21
Regulatory Setbacks In Cell And Gene Therapy Will Eventually Reward Patient Long Term Holders
Catalysts About ClearPoint Neuro ClearPoint Neuro provides minimally invasive neurosurgery systems and tools that support drug, cell and gene therapy delivery to the brain. What are the underlying business or industry changes driving this perspective?Uppdatering av berättelse • Mar 06
CLPT: Broad Biopharma Partnerships Will Support Future Neurology Platform Upside
Analysts have reduced their fair value estimate for ClearPoint Neuro from $29 to $24 and highlighted a lower $18 Street price target, citing higher perceived risk after the FDA feedback on a partner program, while still pointing to a broad biopharma customer base and multiple clinical-stage collaborations as key supports for the updated outlook. Analyst Commentary Bullish Takeaways Bullish analysts still see support for the updated valuation from more than 60 active biopharma partners, which suggests a diversified customer base rather than reliance on a single program.
Ny berättelse • Mar 06
IRRAS Merger And Gene Therapy Ecosystem Will Transform Long Term Neurosurgical Platform Potential
Catalysts About ClearPoint Neuro ClearPoint Neuro develops and sells neurosurgical navigation, drug delivery and cranial access technologies used across preclinical research, clinical trials and hospital procedures. What are the underlying business or industry changes driving this perspective?Analysartikel • Nov 10
ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 39% Cheaper Price Remains In Tune With Revenues
The ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) share price has softened a substantial 39% over the previous 30 days...Analysartikel • Nov 03
Is ClearPoint Neuro (NASDAQ:CLPT) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysartikel • Sep 25
Why Investors Shouldn't Be Surprised By ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) 84% Share Price Surge
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 84% after a shaky period...Analysartikel • May 04
After Leaping 31% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
Those holding ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares would be relieved that the share price has rebounded 31% in...Seeking Alpha • Apr 29
ClearPoint Neuro: Fundamentals Continue To Strengthen
Summary ClearPoint continues to make progress in relation to its LITT and operating room expansion efforts. More importantly, ClearPoint's partners continue to provide positive news in relation to their therapeutic candidates. It will take time for these tailwinds to impact ClearPoint's financials, but 2026/2027 onwards should see a step change in performance. I continue to believe ClearPoint is an attractive investment opportunity, but its high revenue multiple, current lack of profitability and market volatility mean risk is elevated. Read the full article on Seeking Alpha
Ny berättelse • Mar 29
Cell And Gene Therapy Delivery Will Expand Global Partnerships
Strategic partnerships and global expansion aim to boost revenue and earnings through enhanced technology access and new pharma agreements.Analysartikel • Feb 14
After Leaping 25% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have continued their recent momentum with a 25% gain in the last month...Analysartikel • Dec 10
After Leaping 26% ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Are Not Flying Under The Radar
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shareholders have had their patience rewarded with a 26% share price jump in the...Analysartikel • Sep 14
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 28%
Despite an already strong run, ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have been powering on, with a gain of 28...Analysartikel • Aug 16
Is ClearPoint Neuro (NASDAQ:CLPT) Weighed On By Its Debt Load?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Jul 11
Investors Appear Satisfied With ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Prospects As Shares Rocket 26%
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) shares have had a really impressive month, gaining 26% after a shaky period...Analysartikel • May 09
ClearPoint Neuro, Inc. (NASDAQ:CLPT) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) just released its latest first-quarter results and things are looking bullish...Seeking Alpha • Apr 25
ClearPoint Neuro: Macro-Induced Multiple Compression
Summary ClearPoint Neuro's stock is down due to a recent equity raise and concerns about rising interest rates. The company is expanding its product portfolio and driving adoption of existing products with new software releases and FDA clearances. The recent capital raise should be sufficient to see the ClearPoint through to profitability. ClearPoint's valuation is modest given the company's rapid growth and expanding product portfolio. Read the full article on Seeking AlphaAnalysartikel • Apr 19
Are ClearPoint Neuro, Inc. (NASDAQ:CLPT) Investors Paying Above The Intrinsic Value?
Key Insights The projected fair value for ClearPoint Neuro is US$4.02 based on 2 Stage Free Cash Flow to Equity Current...Analysartikel • Mar 15
Analysts Have Made A Financial Statement On ClearPoint Neuro, Inc.'s (NASDAQ:CLPT) Yearly Report
Shareholders of ClearPoint Neuro, Inc. ( NASDAQ:CLPT ) will be pleased this week, given that the stock price is up 19...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur ClearPoint Neuro tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 30 Jun 26 | 42 | -35 | 40 | 16 |
| 31 Mar 26 | 41 | -29 | 35 | 15 |
| 31 Dec 25 | 37 | -26 | 31 | 14 |
| 30 Sep 25 | 34 | -23 | 30 | 14 |
| 30 Jun 25 | 34 | -22 | 29 | 14 |
| 31 Mar 25 | 32 | -21 | 28 | 13 |
| 31 Dec 24 | 31 | -19 | 26 | 12 |
| 30 Sep 24 | 30 | -18 | 25 | 12 |
| 30 Jun 24 | 28 | -18 | 25 | 11 |
| 31 Mar 24 | 26 | -21 | 25 | 11 |
| 31 Dec 23 | 24 | -22 | 24 | 12 |
| 30 Sep 23 | 22 | -22 | 23 | 12 |
| 30 Jun 23 | 22 | -21 | 22 | 12 |
| 31 Mar 23 | 21 | -18 | 21 | 11 |
| 31 Dec 22 | 21 | -16 | 19 | 11 |
| 30 Sep 22 | 20 | -16 | 18 | 11 |
| 30 Jun 22 | 19 | -16 | 18 | 11 |
| 31 Mar 22 | 17 | -16 | 16 | 11 |
| 31 Dec 21 | 16 | -14 | 15 | 9 |
| 30 Sep 21 | 16 | -12 | 14 | 8 |
| 30 Jun 21 | 15 | -9 | 13 | 7 |
| 31 Mar 21 | 14 | -7 | 11 | 5 |
| 31 Dec 20 | 13 | -7 | 11 | 5 |
| 30 Sep 20 | 12 | -7 | 10 | 4 |
| 30 Jun 20 | 12 | -6 | 10 | 3 |
| 31 Mar 20 | 12 | -6 | 10 | 3 |
| 31 Dec 19 | 11 | -6 | 9 | 3 |
| 30 Sep 19 | 10 | -5 | 8 | 3 |
| 30 Jun 19 | 9 | -5 | 8 | 2 |
| 31 Mar 19 | 8 | -6 | 8 | 2 |
| 31 Dec 18 | 7 | -6 | 8 | 2 |
| 30 Sep 18 | 7 | -7 | 8 | 2 |
| 30 Jun 18 | 7 | -7 | 8 | 2 |
| 31 Mar 18 | 7 | -7 | 8 | 3 |
| 31 Dec 17 | 7 | -7 | 8 | 3 |
| 30 Sep 17 | 7 | -7 | 8 | 3 |
| 30 Jun 17 | 7 | -8 | 8 | 3 |
| 31 Mar 17 | 6 | -8 | 8 | 3 |
| 31 Dec 16 | 6 | -8 | 8 | 3 |
| 30 Sep 16 | 6 | -8 | 8 | 3 |
| 30 Jun 16 | 5 | -5 | 8 | 2 |
| 31 Mar 16 | 5 | -7 | 8 | 2 |
| 31 Dec 15 | 5 | -8 | 8 | 2 |
| 30 Sep 15 | 4 | -9 | 9 | 2 |
Kvalitetsintäkter: CLPT är för närvarande olönsam.
Växande vinstmarginal: CLPT är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: CLPT är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 16% per år.
Accelererande tillväxt: Det går inte att jämföra CLPT s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: CLPT är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Medical Equipment branschen ( 15.6% ).
Avkastning på eget kapital
Hög ROE: CLPT har en negativ avkastning på eget kapital ( -320.77% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/09/09 07:37 |
| Aktiekurs vid dagens slut | 2026/09/09 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
ClearPoint Neuro, Inc. bevakas av 7 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Kyle Bauser | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |